ARS Pharmaceuticals (SPRY) Other Operating Expenses (2022 - 2026)

ARS Pharmaceuticals has reported Other Operating Expenses for 5 years, with the latest figure at $6.3 million in Q1 2026.

• Quarterly Other Operating Expenses rose 474.59% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.6 million (up 1136.84% YoY) and the FY2025 annual result came in at $20.4 million, up 1990.38% from the prior year.
• Other Operating Expenses advanced to $6.3 million in Q1 2026 per SPRY's latest filing, from $6.2 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $11.8 million in Q1 2023 and troughed at -$1.1 million in Q3 2022.
• A 5-year average of $4.3 million and a median of $5.0 million in 2025 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses surged 7213.39% in 2025, then soared 474.59% in 2026.
• Over 5 years, Other Operating Expenses stood at -$1.1 million in 2022, then surged by 1182.63% to $11.8 million in 2023, then sank by 92.7% to $865000.0 in 2024, then soared by 611.45% to $6.2 million in 2025, then increased by 2.14% to $6.3 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $6.3 million, $6.2 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.